Elkfork Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Elkfork Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$130K	Hold	1,782	–	–	﹤0.01%	907
2019 Q2	$146K	Hold	1,782	–	–	﹤0.01%	886
2019 Q1	$126K	Hold	1,782	–	–	﹤0.01%	890
2018 Q4	$80K	Hold	1,782	–	–	﹤0.01%	919
2018 Q3	$101K	Buy	1,782 +374	+27%	+$22.9K	﹤0.01%	954
2018 Q2	$94K	Hold	1,408	–	–	﹤0.01%	931
2018 Q1	$82K	Hold	1,408	–	–	﹤0.01%	960
2017 Q4	$91K	Buy	1,408 +198	+16%	+$12.3K	﹤0.01%	947
2017 Q3	$64K	Buy	1,210 +198	+20%	+$9.44K	﹤0.01%	957
2017 Q2	$47K	Buy	1,012 +572	+130%	+$27.6K	﹤0.01%	973
2017 Q1	$22K	Buy	+440	New	+$24.7K	﹤0.01%	986

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Elkfork Partners's ANIP Position: Q3 2019 in Review

Elkfork Partners held its ANI Pharmaceuticals (ANIP) position steady in Q3 2019 at 1,782 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #907.

Elkfork Partners first reported a position in ANIP in Q1 2017 and has held it in 11 quarters since. The position peaked at $146K in Q2 2019. 190 funds tracked by Wall St. Rank hold ANIP as of Q3 2019.

Elkfork Partners held 1,782 shares of ANI Pharmaceuticals worth $130K as of Q3 2019.
Elkfork Partners left its ANI Pharmaceuticals share count unchanged in Q3 2019.
ANI Pharmaceuticals made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #907 holding.
Elkfork Partners first reported a position in ANI Pharmaceuticals in Q1 2017 and has held it in 11 quarters since.
Elkfork Partners's ANI Pharmaceuticals position peaked at $146K in Q2 2019.
190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.